Sangamo Therapeutics Inc
NASDAQ:SGMO
Sangamo Therapeutics Inc
Interest Income Expense
Sangamo Therapeutics Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sangamo Therapeutics Inc
NASDAQ:SGMO
|
Interest Income Expense
$11.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$757m
|
CAGR 3-Years
35%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$563.1m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Sangamo Therapeutics Inc's Interest Income Expense?
Interest Income Expense
11.1m
USD
Based on the financial report for Dec 31, 2023, Sangamo Therapeutics Inc's Interest Income Expense amounts to 11.1m USD.
What is Sangamo Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
6%
Over the last year, the Interest Income Expense growth was 18%. The average annual Interest Income Expense growth rates for Sangamo Therapeutics Inc have been 8% over the past three years , 6% over the past five years .